Is NYC a biotech hub? Gut-brain startup Kallyope, equipped with $66M in new money, says yes
In a win for New York City’s hopeful biotech scene, Columbia University spinout Kallyope has nailed down a $66 million financing round with plans of growing the startup’s staff in NYC’s life science core.
The company got the Series B cash from many of the same investors that contributed to their A round, including Lux Capital, The Column Group, and Illumina Ventures, among others.
Kallyope is led by CEO Nancy Thornberry, a longtime Merck veteran who joined the company in 2015 when there was only six people on staff. Today, the company employs 44 and plans to grow its staff to 60 by the end of this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.